More Venture Funding For Sirtris

Mass High Tech reports on the $13 million A round funding landed by Sirtris Pharmaceuticals - it follows close on the heels of their seed funding earlier this year. Sirtris was founded by David Sinclair to investigate sirtuin enzymes and their role in the health and longevity benefits of calorie restriction. They are "attractive drug targets for metabolism, inflammation, cancer and neurodegeneration." More funding in this area is a good thing - greater understanding of the mechanisms of aging and metabolism should lead to a class of therapies that can extend healthy life span and reduce the risk of suffering age-related conditions. Venture capitalists tend to invest in clusters of related technologies, so we can hope to see similar efforts funded in the years ahead.

Link: http://www.masshightech.com/displayarticledetail.asp?Art_ID=67281

Comments

Post a comment; thoughtful, considered opinions are valued. New comments can be edited for a few minutes following submission. Comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.

Note that there is a comment feed for those who like to keep up with conversations.